News

The In Vitro Diagnostics (IVD) market is experiencing a notable transformation, propelled by technological advancements, changing market dynamics, and evolving regulations. As we move through 2024, the IVD sector is continuing its recovery from the disruptions caused by the COVID-19 pandemic, showcasing a remarkable 6% growth in 2023, indicating a clear rebound and expansion.

This growth has been supported by enhanced capital purchasing, a wider array of assay options, automation solutions, and the diversification of care settings to include pharmacies and at-home testing. While there has been a decline in sales related to COVID-19, the core IVD market remains strong, particularly in core laboratory and Point-of-Care (POC) segments.

Regional Dynamics and Market Leaders

Market dynamics vary across regions. Although all areas faced declines due to decreased COVID-19 sales, many companies have reported positive trends in their underlying businesses. Emerging markets are positioned for growth, thanks to a large, underserved patient population, increasing diagnosis rates, and greater awareness.

Leading companies such as Roche, Mindray, and Sysmex have recorded the highest growth percentages in key core laboratory markets. Alongside major players like Siemens, Abbott, and BioMerieux, these companies are driving industry progress through innovation and strategic positioning.

Future Drivers and Challenges

Looking forward, several factors will influence the IVD market. Stricter regulations, such as FDA/IVDR, tend to favor larger multinational corporations with significant resources and experience. The shift toward POC testing and the expansion of precision medicine beyond oncology into other high-burden areas are expected to be key growth drivers. Additionally, advancements in digital pathology, IT, and AI solutions are likely to improve diagnostic efficiency and accuracy.

However, the industry also faces several challenges. Navigating the complex regulatory environment demands considerable resources and expertise, creating significant hurdles for smaller companies. The competitive landscape, with major players continuously broadening their product offerings and technological capabilities, may lead to market saturation. Furthermore, integrating advanced technologies like AI and digital diagnostics into existing workflows poses challenges, particularly regarding interoperability and data security.

Source: IQVIA MedTech